Asklepios Klinik St George
- Address
- lock Available on a paid plan
Cardiovascular Diseases Research
At Asklepios Klinik St George in Hamburg, clinical trials in cardiovascular diseases focus mainly on atrial fibrillation and the related risk of stroke. These studies are designed to compare ways of preventing embolic events and to better understand how treatment strategies can reduce complications after rhythm procedures.
- Prevention of stroke and systemic embolism in people with atrial fibrillation
- Reducing embolic risk after catheter ablation
- Evaluating new approaches to control atrial fibrillation burden
The research aims to improve everyday care by testing whether newer anticoagulation or rhythm-management strategies can offer safer and more effective protection.
Digestive System Diseases Research
Trials in digestive system diseases at this site are centered on short bowel syndrome and short bowel syndrome-associated intestinal failure. The main goal is to assess new treatments that may improve intestinal function, support long-term safety, and ease the challenges of living with reduced bowel absorption.
- Long-term safety and tolerability of therapies for short bowel syndrome
- Support for patients with intestinal failure and limited nutrient absorption
- Testing medicines intended to improve symptoms and daily management
These studies help clarify whether emerging therapies can better support patients who need ongoing treatment for chronic digestive conditions.
Hemic and Lymphatic Diseases Research
The Department Hematology Oncology and Stem cell research at Asklepios Klinik St George conducts a broad portfolio in hematologic malignancies, including acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, and aggressive forms of lymphoma. The trials are aimed at improving survival, reducing toxicity, and refining treatment choices for both newly diagnosed and relapsed disease.
- Testing new treatment combinations for acute myeloid leukemia and acute lymphoblastic leukemia
- Evaluating approaches that may reduce treatment-related toxicity in lymphoma care
- Studying transplant and cellular therapy strategies for relapsed blood cancers
This research reflects a strong focus on personalized blood cancer treatment, including therapies for patients who need alternatives to standard intensive regimens.
Immune System Diseases and Inflammatory Conditions
Clinical research in immune system diseases at this hospital also includes conditions with strong inflammatory and hormone-related components, such as carcinoid syndrome. The studies are designed to evaluate whether new therapies can better control symptoms and improve quality of life for affected patients.
- Assessing symptom control in carcinoid syndrome
- Exploring treatment options for chronic immune-related and inflammatory disease patterns
- Measuring whether new medicines can improve patient comfort and daily functioning
Although smaller in scope than the oncology and gastrointestinal programs, this area adds important breadth to the site’s clinical trial activity.
Neoplasms Research
Trials in neoplasms form a major part of the research portfolio at Asklepios Klinik St George. The site is studying several cancers, including Hodgkin lymphoma, diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and HPV-positive oropharyngeal cancer. The overall aim is to improve cancer control while reducing treatment burden and preserving function.
- Evaluating novel therapies for relapsed or refractory lymphoma
- Testing treatment strategies for newly diagnosed and high-risk leukemia
- Studying ways to preserve swallowing function and limit toxicity in head and neck cancer
These oncology studies highlight the site’s expertise in advanced cancer care, cellular therapies, and treatment optimization for patients with difficult-to-treat malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 61 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 59 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Asklepios Klinik St George
lock Showing 1 of 29 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 104-week, multicenter, open-label, single-arm, phase 3 extension trial investigating the long-term safety and efficacy of Glepaglutide in adult patients with short bowel syndrome (SBS) rolling over from the EASE SBS 2 or 3 trials | Zealand Pharma A/S | Phase III | Not Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 61 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Glepaglutide | 4 | Unknown | 2019-04-30 | 2026-01-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.